Signos is a San Francisco Bay Area digital health company pairing a continuous glucose monitor with an AI-driven app to help non-diabetic adults lose weight and improve metabolic health through real-time, personalized feedback on food, sleep, stress and exercise.
Vivoo is a San Francisco-based health tech company that makes at-home urine test strips analyzed via smartphone camera. Founded in 2017, the company offers a wellness platform that measures 8+ biomarkers — including hydration, vitamins, minerals, pH, ketones, and oxidative stress — and delivers personalized nutrition and lifestyle recommendations through a free mobile app. Backed by $19.4M in funding led by Tim Draper, Vivoo is sold at Target, Walmart, and Sam's Club, and has expanded to 100+ countries with a focus on making lab-grade health insights accessible to everyday consumers.
Sharam Fouladgar-Mercer is the Co-Founder and CEO of Signos, the company behind the first FDA-cleared over-the-counter glucose monitoring system for weight management. A Princeton computer science graduate and Harvard MBA, he played NCAA Division I ice hockey before building a career spanning VC at Sierra and Shasta Ventures, co-founding PR tech company AirPR (later Onclusive), and ultimately creating Signos in 2018 after his own lifelong struggle with weight and the death of his diabetic grandmother inspired him to ask: why wait until someone is sick to give them metabolic data?